Article
Optimizing Oral Drug Delivery using Zydis® Orally Disintegrating Tablet Technology to Address Patient Challenges
This article looks at how innovation in the industry-leading Zydis ODT platform is expanding oral formulation options and bringing benefits to patients.
View Now
Article
Using Zydis® ODT to Solve Delivery Challenges for Tolerogenic Vaccines
Summary: Using Zydis® orally dissolving tablet (ODT) platform from Catalent as a unique delivery route for allergy immunotherapies.
View Now
eBook
Biologics By Mouth-Leveraging Freeze-Dried Orally Disintegrating Tablets
Summary: Learn more about the role of oral dose delivery for tolerogenic vaccines, fast dissolving tablets and biological APIs.
View Now
Executive Summary
Is My Molecule Suitable for an Orally Disintegrating Tablet?
Summary: While new drug products may benefit from ODT formulation beginning with product launch, ODT formulation can also play a role in life cycle management of approved products.
View Now
Offering Fact Sheet
OptiForm® Solution Suite Bio Capabilities Sheet
OptiForm® Solution Suite Bio is designed to rapidly screen biomolecules’ potential for a non-invasive delivery route.
View Now
Article
Exclusive Orphan Drugs Industry Survey Results Desire to Treat Rare Diseases Tempered by a Lack of Internal Expertise and Capability
Summary: Orphan drugs face obstacles that span from discovery to launch, largely because of small patient populations and limited markets for rare disease therapies.
View Now
Infographic
Zydis® Orally Disintegrating Tablet (ODT) vs. Standard Tablets (ST)
Summary: This infographic provides a high level summary of studies comparing Zydis ODT against traditional oral tablets.
View Now
Webinars
Is My Molecule Suitable for an Orally Disintegrating Tablet?
Summary: This webinar aims to provide clarity on the types of molecules suitable for an ODT format as well as the regulatory pathways for new and established therapies.
View Now
Webinars
Amorphous and Co-Amorphous Systems for Poorly Soluble Drugs
Summary: This webinar provides an overview of co-amorphous research and its recent findings, particularly, the impact of low molecular weight excipient on developability, stability and solubility.
View Now
Presentation
Getting Your Molecule From Preclinical Dev to Phase I
Summary: Three early drug development experts present insights and techniques to help your clients get their molecules from preclinical to Phase 1 studies.
View Now
